Sanofi Receives European Approval for VaxRabeo, Its New Rabies Vaccine
The European Commission has granted VaxRabeo its first marketing authorisation. It covers pre-exposure and post-exposure prophylaxis against rabies for all age groups.
Announced by Sanofi on 19 November 2026, the decision follows the positive opinion issued on 17 September 2026 by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
A Vaccine Derived from the Same Strain as Verorab and Imovax Rabies
VaxRabeo (inactivated rabies virus, Wistar strain) is produced using Vero cell technology. It shares the same viral strain as Verorab and Imovax Rabies, the rabies vaccines already marketed by Sanofi, which the company presents as a “next-generation” vaccine.
The laboratory states that its formulation is designed to minimise the risk of allergic reactions. It also claims a longer shelf life and better thermostability than its current rabies vaccines: 60 months of storage and stability up to 27 °C for 96 hours before reconstitution.
The approved vaccination schedules include a two-dose pre-exposure prophylaxis, in line with World Health Organization (WHO) recommendations. They also provide for a four-dose post-exposure prophylaxis for unvaccinated individuals, with or without rabies immunoglobulins.
According to WHO estimates cited by Sanofi, rabies is present in 150 countries and causes approximately 59,000 deaths per year worldwide. Around 29 million people receive post-exposure vaccination each year. The disease has no treatment and can only be prevented through vaccination.
Antibody Levels Comparable to the Group's Current Vaccines
The authorisation is based on a clinical programme that compared VaxRabeo with Sanofi's current standard treatments, in both pre-exposure and post-exposure settings, for all age groups and according to WHO schedules. The comparator is therefore the group's existing portfolio, and the published results concern the antibody response.
In pre-exposure settings, the two- and three-dose regimens achieved protective antibody levels comparable to those of the two reference vaccines, in adults as well as children. Booster doses administered 12 months, or 24 to 36 months, after the last dose produced a strong boost of the immune response, according to the press release.
In post-exposure settings, the immunogenicity profile is described as similar, with 100% of participants reaching protective antibody levels after intramuscular administration. The group reports an acceptable safety profile, similar to that of existing vaccines, with no significant safety concern identified, whether the vaccine is administered alone or with immunoglobulins.
Thomas Triomphe, head of Sanofi's Vaccines division, stated: “Deaths from rabies must be prevented at all costs; they are entirely preventable through timely vaccination.”